In this article, we will list the 5 Best Up and Coming Stocks with Highest Upside Potential. Please visit 10 Best Up and Coming Stocks with Highest Upside Potential to see the extended list and the methodology behind it.

5. Tempus AI Inc. (NASDAQ:TEM)

Average Upside Potential: 41.04%

Tempus AI Inc. (NASDAQ:TEM) is one of the best up and coming stocks with highest upside potential. On April 23, Tempus AI and the Keck School of Medicine of USC launched a multi-faceted collaboration aimed at integrating artificial intelligence and data-driven insights into Southern California’s healthcare landscape. This partnership will impact over 1.5 million annual patient visits across the USC Norris Comprehensive Cancer Center, Keck Hospital of USC, and other affiliated clinics.

By combining Tempus’ AI-powered diagnostic platform with USC’s clinical expertise, the organizations intend to create a seamless ecosystem that prioritizes personalized care and improves long-term patient outcomes. The collaboration is built upon four foundational pillars: clinical testing, clinical trial matching, care gap pathways, and research co-development.

Through these initiatives, Tempus AI Inc. (NASDAQ:TEM) will integrate advanced molecular diagnostics into Keck Medicine’s workflows and utilize its TIME Trial Program to automate the identification of patients eligible for targeted therapies. Furthermore, AI-driven insights will be deployed to identify and close existing gaps in patient care, ensuring that clinical innovations move responsibly and efficiently from academic research into daily medical practice.

Tempus AI Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

4. Nuvalent (NASDAQ:NUVL)

Average Upside Potential: 41.11%

Nuvalent (NASDAQ:NUVL) is one of the best up and coming stocks with highest upside potential. On April 7, Nuvalent submitted an NDA to the FDA for neladalkib, its investigational ALK-selective inhibitor for patients with advanced ALK-positive non-small cell lung cancer/NSCLC who have previously been treated with tyrosine kinase inhibitors/TKIs. This submission comes less than four years after the initiation of the first clinical trial, reflecting an accelerated development timeline supported by the FDA’s Breakthrough Therapy Designation.

The application is supported by data from the ALKOVE-1 Phase 1/2 clinical trial. In pre-treated patients, neladalkib showed robust anti-tumor activity, including responses in patients with brain metastases. Crucially, the drug’s “ALK-selective, TRK-sparing” design aims to overcome resistance mutations (such as G1202R) caused by earlier-generation inhibitors while avoiding the neurological side effects often associated with off-target TRK inhibition.

Neladalkib is designed to be highly brain-penetrant, addressing a significant clinical need for patients whose cancer has spread to the central nervous system. Nuvalent (NASDAQ:NUVL) continues to enroll participants in the ALKOVE-1 study for other ALK-positive solid tumors and plans to present detailed results from the NSCLC cohort at an upcoming medical meeting.

Nuvalent (NASDAQ:NUVL) is a clinical-stage biopharmaceutical company that develops precisely targeted small molecule therapies for cancer. By using structure-based drug design, the firm creates innovative treatments for kinase targets designed to overcome resistance, address brain metastases, and minimize adverse effects.

3. StandardAero Inc. (NYSE:SARO)

Average Upside Potential: 42.92%

StandardAero Inc. (NYSE:SARO) is one of the best up and coming stocks with highest upside potential. On March 31, StandardAero appointed Giovanni Spitale as President of its Business Aviation segment, effective immediately. Spitale brings over 30 years of global leadership experience to the role, having previously served as CEO of Davis Standard and held senior executive positions at The Boeing Company, GE Aviation, and Honeywell. Based at the company’s Scottsdale headquarters, he will report to COO Kim Ernzen and focus on driving strategic growth and operational excellence for the division.

Spitale succeeds Anthony Brancato III, who is retiring after a distinguished 40-year career in aviation, including nearly a decade at StandardAero. During his tenure, Brancato oversaw significant facility expansions and portfolio innovations while serving as a key advocate for the industry through organizations like the NBAA and GAMA. To ensure a seamless leadership transition, Brancato will remain with the company through June 2026.

A US Navy veteran with a background in nuclear engineering, Spitale is recognized for his ability to scale businesses through both organic growth and strategic acquisitions. His appointment comes at a pivotal time for StandardAero Inc. (NYSE:SARO) as a newly listed public company, following its successful IPO under the ticker SARO.

StandardAero Inc. (NYSE:SARO) is a leading independent maintenance, repair, and overhaul provider serving commercial, military, business aviation, and industrial power customers. The company is headquartered in Scottsdale, Arizona, and was founded in 1911.

2. ESAB Corp. (NYSE:ESAB)

Average Upside Potential: 44.76%

ESAB Corp. (NYSE:ESAB) is one of the best up and coming stocks with highest upside potential. On April 2, ESAB appointed R. Brent Jones as Chief Financial Officer, effective in early May. Jones, a highly experienced executive with over 30 years of financial leadership, succeeds Kevin Johnson, who is departing to join a private firm. Jones previously served as CFO for global organizations such as Avantor and Pall Corporation, and his background includes work in investment banking and corporate law.

In tandem with the leadership change, ESAB reaffirmed its full-year 2026 financial outlook, which was originally issued in February. Despite recent geopolitical volatility, the company remains confident in achieving its core organic sales growth targets. CEO Shyam P. Kambeyanda noted that Jones’s history of navigating international financial environments and delivering value through organic and inorganic growth will be instrumental in accelerating ESAB’s 2028 strategic plans.

Prior to joining ESAB Corp. (NYSE:ESAB), Jones led the global finance organization at Avantor and directed commercial finance and operations at LifeScan. His early career is marked by high-stakes capital markets experience, including overseeing the $13.8 billion sale of Pall Corporation to Danaher.

ESAB Corp. (NYSE:ESAB) is an industrial compounder that manufactures and supplies consumable products and equipment. These include cutting material, consumables & gas controlling solutions, and welding equipment. The company also offers software and digital solutions to enhance productivity and enable remote monitoring of welding operations.

1. GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Average Upside Potential: 48.83%

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best up and coming stocks with highest upside potential. On April 29, GE HealthCare reported total revenues of $5.1 billion for Q1 2026, marking a 7.4% increase, with organic revenue growth contributing 2.9%. This growth was fueled by strong commercial performance in the Pharmaceutical Diagnostics/PDx, Imaging, and Advanced Visualization Solutions segments.

While total organic orders rose by 1.1%, the company maintained a robust backlog of $21.8 billion and a book-to-bill ratio of 1.07 times. Additionally, the quarter was highlighted by the $2.3 billion acquisition of Intelerad, a move intended to strengthen the company’s cloud-based enterprise imaging capabilities. Despite the positive topline results, profitability was pressured by several headwinds, including a temporary PDx supplier issue that has since been resolved. GE HealthCare Technologies Inc. (NASDAQ:GEHC) reported a net income margin of 7.6% and an adjusted EBIT margin of 13.5%, while diluted EPS stood at $0.85 and adjusted EPS at $0.99.

Looking ahead, GE HealthCare has reaffirmed its organic revenue growth guidance of 3.0% to 4.0% based on healthy global demand. However, the company lowered its full-year outlook for profit and free cash flow due to more pronounced inflationary pressures on memory chips, oil, and freight costs. The updated guidance now projects an adjusted EPS range of $4.80 to $5.00 and free cash flow of approximately $1.6 billion.

GE HealthCare Technologies Inc. (NASDAQ:GEHC) is a healthcare company with a focus on various products, services, and digital solutions made for diagnoses and treatments. The company operates through Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.